Academic Literature

Spending On Prescription Drugs In The US: Where Does All…

Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.

HA Blog 07/31/2018

Academic Literature

Association of Rebates in Part D with Patient OOP and…

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.

JAMA Internal Medicine 05/30/2017

Academic Literature

R&D Costs Do Not Explain Elevated U.S. Drug Prices

Drug prices in other high income countries for the 20 top selling drugs globally make up less than half of U.S. net drug prices.

HA Blog 03/07/2017

Reports

Xeljanz, the FDA, and nine years of patient harm

Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action

Drug Pricing Lab 05/31/2022

Reports

Atypical antipsychotics: Decades of use, unfathomable harms

Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly

Drug Pricing Lab 05/31/2022

Reports

Evaluating Industry’s Drug Pricing Claims

A closer look at three of PhRMA’s most cited talking points.

Drug Pricing Lab 11/18/2021

Reports

Biosimilars: Market Changes do not equal policy success

Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.

Drug Pricing Lab 03/15/2021

Reports

Bottom-Up Pricing Estimate for P-quad

How much would biologic drugs cost under P-quad pricing? Two approaches to estimating fully loaded costs plus a profit (10% and 20% examined) suggest net discounts from current prices would be at least 65% to 75%

Drug Pricing Lab 03/12/2021

Academic Literature

US Drug Prices And R&D, Take 2: A Reply To…

To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.

Health Affairs Blog 07/27/2017

Reports

Medicare Part B Premium Dynamics Explained

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Milliman 12/23/2021

Reports

Comparing Factors that Influence Pharmaceutical Pricing and Access in the…

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

Drug Pricing Lab 12/20/2021

Reports

Biosimilars in Medicare Part D: pricing dynamics and considerations

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

Milliman 12/14/2021